IP Library › Granted Patent US 12,576,095
Granted Patent B2
US 12,576,095 · App. 17/944,920 · Granted Mar 17, 2026

Systems and methods for accurate and repeatable delivery of active pharmaceutical ingredients

Inventors: William Warren (Lafayette, CA); Walter Lee Smith (Danville, CA)
Assignee: Transport Authority, Inc.
A61K31/675A61J3/00A61K31/4045A61K31/658
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,576,095
App. No.
17/944,920
Granted
Mar 17, 2026
Kind
B2
Abstract

This present disclosure provides reliable methods and apparatus for delivering microdroplets containing an active pharmaceutical ingredient (API) to underlying substrates. A control system is provided to ensure that the API dosage is both accurate and repeatable.

Claims (27)

1 . A method of limiting error rates in an API dosing system, the method comprising the steps of:

delivering microdroplets of a liquid successively from at least one dosing head to a substrate along a path, wherein the liquid contains a quantity of active pharmaceutical ingredient;

imaging the successively delivered microdroplets at a location between the at least one dosing head and the substrate along the path; and

based on the imaging step, determining a total volume of the liquid that has been delivered to the substrate;

comparing the total volume of liquid that has been delivered to the substrate to a predetermined volume of liquid to be delivered to the substrate; and

discontinuing the delivering step when the total volume is within a selected tolerance, wherein the selected tolerance is within 10% of the predetermined volume of liquid.

2 . The method of claim 1 , wherein the selected tolerance is 1%.

3 . The method of claim 1 , further comprising the step of determining in real time when delivery of a select microdroplet to the substrate would cause the total volume of liquid to be greater than the predetermined volume of liquid.

4 . The method of claim 3 , comprising the step of discontinuing the delivering based on the determining step.

5 . The method of claim 4 , comprising performing the step of discontinuing prior to delivering the select microdroplet when the delivery of the select microdroplet would cause the total volume of liquid that has been delivered to be greater than a sum of the predetermined volume of liquid and one-half of a projected volume of the select microdroplet.

6 . The method of claim 5 , comprising the step of allowing the select microdroplet to be delivered when the delivery of the select microdroplet causes the total volume of liquid that has been delivered to be less than the sum of the predetermined volume of liquid and one-half of a projected volume of the select microdroplet.

7 . The method of claim 5 , comprising performing the step of discontinuing immediately after delivering the select microdroplet when the total volume of liquid that has been delivered is greater than the predetermined volume of liquid.

8 . The method of claim 1 , wherein all microdroplets are delivered successively from a single dosing head, and the imaging step comprises imaging each of the microdroplets with a single camera.

9 . The method of claim 2 , wherein the delivering step comprises a delivering a first plurality of the microdroplets from a first dosing head to the substrate, and delivering at least one second microdroplet from a second dosing head to the substrate.

10 . The method of claim 9 , wherein the at least one second microdroplet is sized less than the microdroplets of the first plurality of the microdroplets.

11 . The method of claim 10 , further comprising the step of determining in real time when delivery of a select second microdroplet of the at least one second microdroplet to the substrate would cause the total volume of liquid to be greater than the predetermined volume of liquid.

12 . The method of claim 11 , comprising the step of discontinuing the delivering step based on the determining step when it is determined that delivery of the select second microdroplet of the at least one second microdroplet to the substrate would cause the total volume of liquid to be greater than the predetermined volume of liquid.

13 . The method of claim 12 , comprising performing the discontinuing step prior to delivering the select second microdroplet when the delivery of the select second microdroplet would cause the total volume of liquid that has been delivered to be greater than a sum of the predetermined volume of liquid and one-half of a projected volume of the select second microdroplet.

14 . The method of claim 13 , comprising the step of allowing the select second microdroplet to be delivered when the delivery of the select second microdroplet causes the total volume of liquid that has been delivered to be less than the sum of the predetermined volume of liquid and one-half of a projected volume of the select second microdroplet.

15 . The method of claim 14 , comprising performing the discontinuing step immediately after delivering the select second microdroplet when the total volume of liquid that has been delivered is greater than the predetermined volume of liquid.

16 . The method of claim 1 , wherein the imaging step is performed at a location along the path whereby the microdroplets are substantially spherical.

17 . The method of claim 1 , wherein the imaging step is performed along a trajectory that intersects the path.

18 . The method of claim 1 , wherein the API comprises cannabis.

19 . The method of claim 18 , wherein the cannabis comprises a cannabinoid including at least one of TCH and CBD.

20 . The method of claim 1 , wherein the API comprises at least one terpene.

21 . The method of claim 1 , wherein the API comprises at least one of psilocybin and psilocyn.

22 . The method of claim 1 , wherein the API comprises a synthetic opioid.

Assignments (2)
CHANGE OF NAME Recorded Nov 23, 2022
From: ATOMIC HEALTH, INC.
To: TRANSPORT AUTHORITY, INC.
Reel/Frame 061989/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2022
From: WARREN, WILLIAM; SMITH, WALTER LEE
To: ATOMIC HEALTH, INC.
Reel/Frame 061627/0936 →
Continuity (2)
Provisional Application 63244031 · Sep 14, 2021
Related Publication 20230077762A1 · Mar 16, 2023
References Cited (98)
US 4322449A · Voss et al. · 1982 [cited by applicant]
US 7090858B2 · Jayaraman · 2006 [cited by applicant]
US 7325548B2 · Enslin · 2008 [cited by applicant]
US 7900850B2 · Zengerle et al. · 2011 [cited by applicant]
US 8071049B2 · Koltay et al. · 2011 [cited by applicant]
US 8910630B2 · Todd · 2014 [cited by applicant]
US 9380813B2 · Mccullough · 2016 [cited by applicant]
US 9474304B2 · Born et al. · 2016 [cited by applicant]
US 9526792B1 · Degeeter · 2016 [cited by applicant]
US 9854828B2 · Langeland · 2018 [cited by applicant]
US 9937147B2 · Degeeter · 2018 [cited by applicant]
US 9974333B1 · Disner · 2018 [cited by applicant]
US 10239069B2 · Rogers · 2019 [cited by applicant]
US 10265362B2 · Schaneville · 2019 [cited by applicant]
US 10369178B2 · Greenbaum et al. · 2019 [cited by applicant]
US 10383358B2 · Kaplan et al. · 2019 [cited by applicant]
US 10485373B1 · Millikin et al. · 2019 [cited by applicant]
US 20040086603A1 · Shastry · 2004 [cited by examiner]
US 20060000470A1 · Clarke · 2006 [cited by examiner]
US 20060002986A1 · Clarke · 2006 [cited by examiner]
US 20060003989A1 · Quay · 2006 [cited by examiner]
US 20070141198A1 · Yang · 2007 [cited by applicant]
US 20070275333A1 · Neuefeind et al. · 2007 [cited by applicant]
US 20080160787A1 · Lehmann · 2008 [cited by applicant]
US 20090181080A1 · Kottayil et al. · 2009 [cited by applicant]
US 20100136123A1 · Izumida et al. · 2010 [cited by applicant]
US 20110177141A1 · Celeste · 2011 [cited by applicant]
US 20120282317A1 · Ekstein · 2012 [cited by applicant]
US 20130011523A1 · Belzowski et al. · 2013 [cited by applicant]
US 20130011525A1 · Belzowski et al. · 2013 [cited by applicant]
US 20130011529A1 · Belzowski et al. · 2013 [cited by applicant]
US 20130087144A1 · Todd · 2013 [cited by applicant]
US 20130089600A1 · Winnicki · 2013 [cited by applicant]
US 20130184354A1 · Jackson et al. · 2013 [cited by applicant]
US 20150257407A1 · Glazier et al. · 2015 [cited by applicant]
US 20160051480A1 · Taha · 2016 [cited by applicant]
US 20160256411A1 · Aung-Din · 2016 [cited by applicant]
US 20160296474A1 · Romanoschi et al. · 2016 [cited by applicant]
US 20160354561A1 · Mccullough · 2016 [cited by applicant]
US 20170016836A1 · Van Den Brink et al. · 2017 [cited by applicant]
US 20170050010A1 · Mcallister et al. · 2017 [cited by applicant]
US 20170112188A1 · Ostrander · 2017 [cited by applicant]
US 20170119660A1 · Temtsin-Krayz et al. · 2017 [cited by applicant]
US 20170172977A1 · Kleidon et al. · 2017 [cited by applicant]
US 20170196923A1 · Moore · 2017 [cited by applicant]
US 20170245550A1 · Freelander · 2017 [cited by applicant]
US 20170368021A1 · Atkinson et al. · 2017 [cited by applicant]
US 20180117161A1 · Docherty et al. · 2018 [cited by applicant]
US 20180140965A1 · Flora et al. · 2018 [cited by applicant]
US 20180141277A1 · Warner et al. · 2018 [cited by applicant]
US 20180221332A1 · Renwick et al. · 2018 [cited by applicant]
US 20180297726A1 · Ruben · 2018 [cited by applicant]
US 20190001087A1 · Davidson et al. · 2019 [cited by applicant]
US 20190015383A1 · Woelfel et al. · 2019 [cited by applicant]
US 20190022055A1 · Siegel et al. · 2019 [cited by applicant]
US 20190030101A1 · Cooper et al. · 2019 [cited by applicant]
US 20190073127A1 · Ravindranath · 2019 [cited by applicant]
US 20190082728A1 · Eaton · 2019 [cited by applicant]
US 20190116808A1 · Tedeschi et al. · 2019 [cited by applicant]
US 20190192428A1 · Goskonda et al. · 2019 [cited by applicant]
US 20190195852A1 · Bryant et al. · 2019 [cited by applicant]
US 20190373679A1 · Fu et al. · 2019 [cited by applicant]
US 20200330424A1 · Bruun et al. · 2020 [cited by applicant]
US 20200352826A1 · Warren · 2020 [cited by examiner]
US 20200393480A1 · Daume et al. · 2020 [cited by applicant]
CA 2984915A1 · 2017 [cited by applicant]
CA 2969158A1 · 2018 [cited by applicant]
CA 3040547C · 2021 [cited by applicant]
CN 109999932A · 2019 [cited by applicant]
JP 11235164A · 1999 [cited by applicant]
JP 2006504671A · 2002 [cited by applicant]
JP 2005531330A · 2005 [cited by applicant]
JP 2013521811A · 2013 [cited by applicant]
JP 2013521812A · 2013 [cited by applicant]
JP 2013521813A · 2013 [cited by applicant]
JP 2017517295A · 2017 [cited by applicant]
JP 2018505912A · 2018 [cited by applicant]
JP 2018507262A · 2018 [cited by applicant]
KR 1020110088991A · 2011 [cited by applicant]
WO 9942000A1 · 1999 [cited by applicant]
WO 2004016246A1 · 2004 [cited by applicant]
WO 2005123569A2 · 2005 [cited by applicant]
WO 2015164840A1 · 2015 [cited by applicant]
WO 2016094810A2 · 2016 [cited by applicant]
WO 2016141056A1 · 2016 [cited by applicant]
WO 2017027528A1 · 2017 [cited by applicant]
WO 2019014631A1 · 2019 [cited by applicant]
WO 2019073127A2 · 2019 [cited by applicant]
Thompson et al., Sequential deposition of overlapping droplets to form a liquid line, J. Fluid Mech, 2014, vol. 761, 261-281. [cited by applicant]
Fan et al., “Development of a drop-on-demand droplet generator for one-drop-fill technology”, Sensors and Actuators A: Physical, 147, 2008, 649-655. [cited by applicant]
Greenberg, Cannabis Scientists Are Chasing the Perfect High, The New York Times Magazine, https://www,nytimes.com/2020/04/01/magazine/cannabis-science.html, Apr. 1, 2020. [cited by applicant]
Hadzhykanova, E. “Edible Dosage Chart: How Much Is Enough”, pp. 15, Honest Mariuana.pdf at Adobe Acrobat Pro (32 bit). (Year: 2016). [cited by applicant]
Helena Miles, “Microdosing Cannabis: The Ultimate Beginne s Guide”, Wayback Machine—https://web.archive.Jrg/web/20191117102654/https://greencamp.com/microdosing, Feb. 14, 2019, pp. 1-6. [cited by applicant]
International Search Report and Written Opinion dated Jul. 29, 2020 issued in PCT/US2020/031128; 18 Pages. [cited by applicant]
JP-2006504671-A Machine Translation 31 pages (Year: 2006). [cited by applicant]
Levet et al., Formulation Development—Solubility-Enhancing Technologies in Pharmaceutical Development, a Mini-Review, Drug Development & Delivery, https://drug-dev.com/formulation-development-solubility-enhancing-techno… [cited by applicant]
Miles, Helena, “Microdosing Cannabis: The Ultimate Beginner's Guide”. The Ultimate Beginner_s.pdf. (Year: 2019). [cited by applicant]
Peshkovsky, Are Cannabinoids More Effective in Nano Form?, Sonomechanics Blog, Industrial Sonomechanics, May 28, 2016. [cited by applicant]